Montreal's ProMetic Life Sciences Inc has entered into a technology transfer and licensing agreement with Brazil's Tecpar for the manufacture of a complex biopharmaceutical product for the South American market. The agreement combines a proprietary manufacturing process licensed from the National Research Council's Biotechnology Research Institute and ProMetic's bioseparation process using Mimetic Legand technology. Prometic will receive $9 million in licence, milestone and development payments, while state-owned Tecpar will spend $10 million to modify its existing facility. The project is expected to lead to a centre of excellence where other drugs can be produced. It also represents a key advance in ProMetic's global strategy for licensing enabling technologies....